Sinonasal Undifferentiated Carcinoma: Disease Characteristics Report

Target disease: Sinonasal undifferentiated carcinoma (SNUC)
Category: Rare, high-grade epithelial malignancy of the nasal cavity and paranasal sinuses
Evidence scope: Disease-level synthesis from peer-reviewed human studies and reviews, supplemented by interventional-trial records. It is not an individual-patient/EHR analysis. Because historical “SNUC” series included tumors now recognized as NUT carcinoma and SMARCB1- or SMARCA4-deficient carcinoma, older estimates require caution.

Executive summary

SNUC is a rapidly progressive, poorly differentiated carcinoma arising in the sinonasal tract. Modern pathology treats it as a diagnosis of exclusion, not a generic label for every undifferentiated sinonasal tumor. Genuine SNUC commonly carries a somatic IDH2 p.Arg172 hotspot mutation, whereas SWI/SNF-deficient sinonasal carcinomas are separate entities. Most patients present in the fifth to sixth decade with obstruction, epistaxis, headache, or visual symptoms and already have extensive local disease. Management is multidisciplinary and generally combines platinum-based chemotherapy, radiotherapy, and selected surgery. The strongest contemporary treatment-selection evidence supports using response to induction chemotherapy to guide definitive chemoradiation versus surgery. Prospective phase II studies are now testing pembrolizumab-containing induction therapy and enasidenib for IDH2-mutant recurrent or metastatic disease. (thawani2023thecontemporarymanagement pages 12-14, NCT05925491 chunk 1, thawani2023thecontemporarymanagement pages 14-15, NCT06176989 chunk 1, mito2018immunohistochemicaldetectionand pages 1-2, agaimy2022proceedingsofthe pages 1-2)

The principal quantitative findings are summarized below.

Table: This table compiles the most supported, SNUC-specific findings available from the gathered sources, emphasizing quantitative epidemiology, presentation, molecular features, treatment outcomes, and active trials. It also explicitly flags when a statistic applies to all sinonasal malignancies rather than genuine SNUC.

1. Disease information

Definition and classification

SNUC is a rare, highly aggressive carcinoma of the nasal cavity or paranasal sinuses showing epithelial differentiation but no definable squamous, glandular, melanocytic, lymphoid, or neuroendocrine lineage. It was first described in 1986 in eight patients and was initially thought to arise from Schneiderian epithelium or nasal ectoderm. Contemporary classification has narrowed the diagnosis by removing molecularly defined mimics from the former “wastebasket” category. (turrizanoni2022molecularbiomarkersin pages 5-6, thawani2023thecontemporarymanagement pages 12-14, thawani2023thecontemporarymanagement pages 14-15)

A useful exact description from the 2018 molecular-pathology study is that SNUC “is considered a diagnosis of exclusion, and has historically represented a heterogeneous group of tumors.” That study showed why combined morphology, immunohistochemistry, and sequencing are now necessary. (mito2018immunohistochemicaldetectionand pages 1-2)

Identifiers and synonyms

• Preferred name: sinonasal undifferentiated carcinoma.
• Synonyms: SNUC; undifferentiated carcinoma of the sinonasal tract; undifferentiated carcinoma of the nasal cavity and paranasal sinuses.
• MONDO/OMIM/Orphanet: A confidently verified disease-specific identifier was not available in the retrieved evidence; these fields should remain unresolved rather than assigning an identifier for a broader sinonasal cancer.
• ICD-10-CM: No histology-specific SNUC code. Coding is anatomical, usually C30.0 (malignant neoplasm of nasal cavity) or a C31.x paranasal-sinus code.
• ICD-O: Registration requires a topography code for the involved sinonasal site plus the applicable undifferentiated-carcinoma morphology code; local registry verification is advised.
• MeSH: No clearly verified SNUC-specific descriptor was identified; indexing generally uses broader “Paranasal Sinus Neoplasms,” “Nasal Cavity Neoplasms,” and “Carcinoma, Undifferentiated.”

These are aggregated disease-resource mappings, whereas the clinical and molecular evidence below derives from cohorts, case series, pathology collections, and trial registries.

2. Etiology, risk, and protective factors

Causal and susceptibility factors

The initiating cause is unknown. SNUC is ordinarily a sporadic somatic cancer, not a Mendelian syndrome. Recurrent IDH2 mutations define a large molecular subgroup but are tumor drivers/biomarkers rather than inherited susceptibility variants. No validated germline causal gene, founder mutation, carrier frequency, penetrance estimate, or familial inheritance pattern has been established. (thawani2023thecontemporarymanagement pages 14-15, mito2018immunohistochemicaldetectionand pages 1-2)

Possible environmental associations are weak and largely hypothesis-generating. Seven of eight patients in the original series had tobacco exposure; individual occupational histories included coal work and chrome plating with exposure to sulfuric/chromic acids, nickel, zinc, copper, and metallic dust. Nickel refining and softwood/furniture exposure have also been reported. These observations are too sparse and confounded to establish causality. (thawani2023thecontemporarymanagement pages 12-14)

EBV is not established as causal. One geographically stratified study detected EBV RNA in 7/11 Asian cases but 0/11 Western cases; a later Taiwanese series found no EBV in 36 cases, and additional studies failed to confirm an association. HPV DNA likewise is generally absent; p16 staining should not be interpreted as proof of HPV-driven disease. (thawani2023thecontemporarymanagement pages 12-14, thawani2023thecontemporarymanagement pages 14-15)

Protective factors and gene–environment interaction

No genetic protective allele, diet, medication, vaccine, or lifestyle intervention has been shown specifically to prevent SNUC. No reproducible gene–environment interaction has been demonstrated. Avoidance of tobacco and recognized occupational carcinogens is prudent general cancer prevention, but its SNUC-specific effect size is unknown.

3. Phenotypes

SNUC usually has adult, insidious onset followed by rapid progression. Symptoms often mimic benign rhinosinusitis, delaying diagnosis. In a systematic review of 140 patients, nasal obstruction occurred in 20.0%, epistaxis in 17.1%, diplopia or other visual symptoms in 15.0%, and headache in 12.1%; orbital involvement was present in 42.9%. In another 128-patient analysis, 72.9% had stage IV disease at diagnosis. (thawani2023thecontemporarymanagement pages 12-14)

Suggested phenotype annotations include:

• Nasal obstruction — HP:0001742, Nasal obstruction; progressive, sometimes unilateral.
• Epistaxis — HP:0000421.
• Headache — HP:0002315.
• Diplopia — HP:0000651.
• Visual impairment — HP:0000505; may result from orbital/apical or optic-pathway invasion.
• Proptosis — HP:0000520, when orbital extension displaces the globe.
• Facial pain — HP:0010828; cranial neuropathy or facial numbness may accompany perineural/skull-base spread.
• Anosmia — HP:0000458, biologically plausible with superior nasal/olfactory involvement, although a reliable SNUC-specific frequency was not retrieved.
• Cervical lymphadenopathy — HP:0025280, reflecting regional metastasis.

Severity is commonly high and progression continuous rather than episodic. Quality of life can be impaired by nasal obstruction, bleeding, pain, disturbed vision, cranial-nerve dysfunction, disfigurement, and treatment effects on smell, vision, swallowing, speech, dentition, endocrine function, and cognition. No validated SNUC-specific EQ-5D, SF-36, or PROMIS distribution was identified; quantitative quality-of-life claims should therefore not be extrapolated from mixed sinonasal cohorts.

4. Genetic, molecular, and epigenetic information

IDH-defined genuine SNUC

The best-established alteration is a somatic IDH2 hotspot mutation at codon R172, with reported frequencies of 10/16 (62.5%), 6/11 (54.5%), and 14/17 (82.4%) across molecular series. In a 193-tumor multi-institutional study, mutation-specific IDH1/2 immunohistochemistry was positive in 26/53 SNUCs (49%) and 0/132 histologic mimics. Sequencing found frequent IDH2 R172 substitutions—R172S/G associated with strong staining and R172T with weak or sometimes negative staining—and a rare IDH1 p.R132C mutation. Consequently, negative mutation-specific IHC does not exclude an IDH mutation; sequencing is required when suspicion remains. (thawani2023thecontemporarymanagement pages 14-15, mito2018immunohistochemicaldetectionand pages 1-2)

Reported co-alterations include TP53, CDKN2A/CDKN2B loss, MYC amplification, SETD2, activating KIT, and PI3K-pathway mutations. In one 12-case IDH2-mutant set, TP53 alterations occurred in 41.7%, CDKN2A/2B loss and MYC amplification each in 33.3%, and SETD2 mutation in 25%. A separate analysis reported TP53 in 55%, activating KIT alterations in 45%, and PI3K-pathway alterations in 36% of IDH-mutant carcinomas. These are somatic tumor findings and are not established ACMG-classified germline variants. (thawani2023thecontemporarymanagement pages 14-15, mito2018immunohistochemicaldetectionand pages 1-2)

Mechanistically, neomorphic mutant IDH2 is expected to convert α-ketoglutarate to the oncometabolite D-2-hydroxyglutarate, inhibiting α-ketoglutarate-dependent dioxygenases and producing widespread epigenetic/differentiation abnormalities. This mechanistic model is biologically well established across IDH-mutant cancers, but SNUC-specific methylome, metabolomic, and causal functional data remain limited.

Suggested annotations: IDH2 (HGNC:5383); IDH1 (HGNC:5382); GO:0045944 positive regulation of transcription, GO:0016491 oxidoreductase activity, GO:0007049 cell cycle, GO:0006281 DNA repair, GO:0043067 regulation of programmed cell death, and GO:0048870 cell motility.

Critical distinction from SWI/SNF-deficient tumors

Historical reports sometimes counted loss of SMARCB1/INI1 or SMARCA4/BRG1 as SNUC alterations. Current expert pathology instead recognizes SMARCB1-deficient sinonasal carcinoma, SMARCB1-deficient adenocarcinoma, SMARCA4-deficient carcinoma, and SMARCA4-deficient teratocarcinosarcoma as distinct SWI/SNF-driven entities. The pathology overview states that studied SWI/SNF-deficient tumors lacked the oncogenic IDH2 mutations “characteristic of genuine SNUC.” (agaimy2022proceedingsofthe pages 1-2)

Thus, loss of nuclear INI1 or BRG1 should prompt reclassification rather than annotation as a SNUC “causal gene.” SMARCB1 maps to 22q11.2 and SMARCA4 to chromosome 19; their proteins are chromatin-remodeling tumor suppressors. In SWI/SNF-deficient tumors, biallelic deletion or inactivating mutation causes protein loss and altered transcriptional/differentiation programs. (thawani2023thecontemporarymanagement pages 14-15, agaimy2022proceedingsofthe pages 1-2)

No validated SNUC modifier genes, germline pathogenic variants, recurrent constitutional chromosomal abnormality, or population allele-frequency estimates were identified. WES/WGS, single-cell, spatial-transcriptomic, proteomic, lipidomic, and metabolomic findings remain research-grade rather than validated disease characteristics.

5. Environmental and infectious information

Potential non-genetic contributors are tobacco and occupational exposure to nickel, chromium/chromic acid, metallic dust, coal-related material, and wood/furniture dust, but evidence is based on very small historical series. Alcohol, diet, exercise, radiation, ambient air pollution, and specific medications have no established SNUC-specific associations. EBV and HPV are not accepted etiologic agents for genuine SNUC. (thawani2023thecontemporarymanagement pages 12-14, thawani2023thecontemporarymanagement pages 14-15)

6. Mechanism and pathophysiology

A defensible causal model is:

1. Upstream event: an acquired epithelial-cell driver, commonly IDH2 R172 mutation, arises in sinonasal mucosa.
2. Molecular consequence: mutant enzyme generates D-2-hydroxyglutarate, plausibly disrupting dioxygenase-dependent chromatin regulation and differentiation.
3. Cellular consequence: lineage maturation fails while proliferation, cell-cycle activity, DNA-repair programs, invasion, and survival pathways become dysregulated. Gene-expression comparison with sinonasal squamous carcinoma identified differences involving CLCA2, ARID2, MAP1LC3A, SMAD4, HELLS, MAPKAPK5-AS1, and KRT16, although direction and functional importance require further validation. (thawani2023thecontemporarymanagement pages 14-15)
4. Tissue consequence: sheets/nests of high-grade epithelial cells develop necrosis, marked mitotic activity, lymphovascular invasion, perineural invasion, and destructive growth through bone.
5. Clinical consequence: obstruction and bleeding arise locally; orbital/skull-base invasion produces visual and neurologic symptoms; lymphovascular dissemination produces cervical-node and distant metastases. (thawani2023thecontemporarymanagement pages 12-14, thawani2023thecontemporarymanagement pages 14-15)

Relevant cell ontology suggestions are CL:0000066 epithelial cell, CL:0000115 endothelial cell for vascular invasion, CL:0000235 macrophage, and CL:0000084 T cell for the tumor microenvironment. The precise tumor cell of origin is unresolved. Suggested biological-process terms include GO:0008283 cell population proliferation, GO:0007155 cell adhesion, GO:0030335 positive regulation of cell migration, GO:0001525 angiogenesis, GO:0006915 apoptotic process, and GO:0006355 regulation of DNA-templated transcription.

No reproducible SNUC-specific immune-cell atlas, immune-evasion mechanism, metabolic signature beyond the inferred IDH oncometabolite pathway, or CRISPR dependency screen was found.

7. Anatomical structures affected

The primary sites are the nasal cavity (UBERON:0001707) and paranasal sinuses (UBERON:0001825), particularly ethmoid, maxillary, sphenoid, and frontal sinuses. Contiguous spread may involve sinonasal mucosa, bone, orbit, cribriform plate, anterior or middle cranial fossa, dura, brain, cranial nerves, nasopharynx, clivus, palate, pterygoid structures, and facial soft tissue. AJCC T4b disease includes orbital apex, middle cranial fossa, dura, brain, non-V2 cranial nerves, nasopharynx, or clivus. (thawani2023thecontemporarymanagement pages 62-70, thawani2023thecontemporarymanagement pages 14-15)

At tissue level this is an epithelial malignancy with destructive invasion into connective tissue, bone, vessels, nerves, and sometimes neural tissue. Regional dissemination involves cervical lymph nodes; distant sites include lung, bone, brain, and liver. Disease is usually centered asymmetrically or unilaterally but can cross midline when extensive. Nuclear and cytosolic compartments are mechanistically relevant to transcription/chromatin regulation and IDH2 metabolism, respectively.

8. Temporal development

Presentation is generally in middle-aged or older adults, with median age approximately 50–60 years. Onset is often clinically insidious because early symptoms resemble inflammatory sinonasal disease, but biological progression is rapid. Most tumors are locally advanced at diagnosis, and the course without effective treatment is progressive rather than relapsing-remitting. (thawani2023thecontemporarymanagement pages 12-14)

Staging should use AJCC eighth-edition site-specific TNM. Modified Kadish staging is also reported: stage A is confined to the nasal cavity, while stage D denotes nodal or distant metastasis. Treatment-induced remission can occur, especially after platinum-based induction therapy, but local, regional, and distant relapse remain important. No credible spontaneous-remission pattern is established. The early induction-chemotherapy response interval is a critical decision window because response strongly informs the choice of definitive local therapy. (thawani2023thecontemporarymanagement pages 14-15)

9. Inheritance, epidemiology, and population

SNUC accounts for approximately 3–5% of sinonasal carcinomas/malignancies. SEER recorded 318 cases from 1973–2010, corresponding to an annual incidence of approximately 0.02 per 100,000. Incidence was estimated at 0.03 per 100,000 in males and 0.01 in females, implying roughly a 3:1 incidence ratio. The median age is 50–60 years. (thawani2023thecontemporarymanagement pages 12-14, mito2018immunohistochemicaldetectionand pages 1-2)

For context, all sinonasal malignancies together occur at approximately 0.5–1.0 per 100,000; that broader statistic must not be assigned to SNUC itself. (thawani2023thecontemporarymanagement pages 14-15)

No reliable ethnic predisposition, endemic distribution, founder effect, consanguinity association, anticipation, mosaicism, carrier state, or reproductive recurrence risk is established. Because the relevant variants are usually somatic, Mendelian inheritance fields are not applicable.

10. Diagnostics

Clinical and imaging work-up

Evaluation should include nasal endoscopy, contrast-enhanced CT for bone destruction, and contrast-enhanced MRI for orbit, skull base, dura, brain, and perineural disease. Typical imaging shows a large, noncalcified invasive mass; MRI is approximately isointense to muscle on T1, iso- to hyperintense on T2, and heterogeneously enhancing after gadolinium. Chest/body imaging or FDG-PET/CT is appropriate for nodal and distant staging. Imaging is not histologically specific. (thawani2023thecontemporarymanagement pages 14-15)

Biopsy and pathology

Histology shows small-to-medium pleomorphic cells in ribbons, sheets, nests, trabeculae, or organoid arrangements, with scant cytoplasm, hyperchromatic nuclei, prominent nucleoli, high mitotic activity, necrosis, and possible lymphovascular/perineural invasion. Broad-spectrum epithelial markers support carcinoma: AE1/AE3, CAM5.2, CK7, CK8, and CK19 are commonly positive or variably expressed. (thawani2023thecontemporarymanagement pages 14-15, thawani2023thecontemporarymanagement pages 12-14)

A practical exclusion panel should include:

• p40/CK5/6: usually negative in genuine SNUC; diffuse positivity favors squamous carcinoma.
• S100/SOX10 and melanocytic markers Melan-A/HMB45: exclude melanoma and selected neural/multiphenotypic tumors.
• CD45: excludes lymphoma.
• Desmin/myogenin: exclude rhabdomyosarcoma.
• Synaptophysin/chromogranin/INSM1: evaluate neuroendocrine carcinoma; focal neuroendocrine-marker expression can occur in SNUC without neuroendocrine morphology.
• NUT IHC: excludes NUT carcinoma.
• INI1/SMARCB1 and BRG1/SMARCA4: retained expression supports genuine SNUC; loss defines separate SWI/SNF-deficient entities.
• EBER-ISH: excludes EBV-associated nasopharyngeal-type carcinoma/NK-T-cell processes where appropriate.
• Mutation-specific IDH1/2 IHC followed by tumor NGS: identifies the IDH-mutant subgroup, but sequencing is essential after negative/weak IHC because R172T and rare IDH1 variants may be missed. (thawani2023thecontemporarymanagement pages 14-15, mito2018immunohistochemicaldetectionand pages 1-2, agaimy2022proceedingsofthe pages 1-2)

Genetic and omics testing

The clinically relevant test is somatic tumor profiling, preferably an NGS panel covering IDH2 R172/R140, IDH1 R132, TP53, CDKN2A/B, MYC copy number, PI3K-pathway genes, and other actionable alterations. RNA sequencing may be used if a fusion-defined differential remains possible. WES/WGS can help difficult cases but has no established advantage over focused DNA/RNA profiling in routine SNUC. Germline testing, CMA, karyotyping, mitochondrial testing, and repeat-expansion testing are not routine unless personal/family history independently suggests a hereditary syndrome.

Differential diagnosis and screening

Major alternatives are olfactory neuroblastoma, high-grade neuroendocrine carcinoma, poorly differentiated squamous carcinoma, NUT carcinoma, SMARCB1- or SMARCA4-deficient carcinoma, lymphoma, melanoma, rhabdomyosarcoma, Ewing sarcoma, and EBV-associated carcinoma. Precise separation is mandatory because prognosis and targeted trials differ. (mito2018immunohistochemicaldetectionand pages 1-2, agaimy2022proceedingsofthe pages 1-2)

There is no population screening test, blood biomarker, liquid-biopsy standard, carrier screen, or surveillance program for asymptomatic individuals.

11. Outcome and prognosis

SNUC has historically had poor outcomes, with an often-cited median survival of approximately 22 months despite multimodal therapy. Regional metastasis occurs in approximately 5–16% and distant metastasis in 20–30%. (thawani2023thecontemporarymanagement pages 12-14, mito2018immunohistochemicaldetectionand pages 1-2)

Outcomes vary substantially with stage, resectability, radiotherapy dose, treatment combination, and induction response. A review table reported historical five-year overall survival of 19% with radiotherapy alone versus 46% with surgery plus radiotherapy in one series, and 60% versus 9%, respectively, in another. In the modern induction-guided cohort, summarized five-year survival was 66% for induction chemotherapy followed by chemoradiation and 43% for induction followed by surgery and radiotherapy; corresponding progression-free estimates were 74% and 55%. These nonrandomized comparisons are subject to response-based selection and should not be interpreted as universal regimen effects. (konig2020theroleof pages 5-6)

Across a meta-analysis, locoregional control was 63.9% with trimodality therapy, 49.2% with bimodality therapy, and 31.3% with surgery alone; another meta-analysis did not find a survival advantage for three modalities over two, though combination treatment remained superior to a single modality. (thawani2023thecontemporarymanagement pages 14-15)

Adverse prognostic features include T4/skull-base or intracranial extension, nodal/distant disease, inability to deliver definitive local treatment, and poor induction-chemotherapy response. IDH-mutant tumors may have a more favorable biology in some series, but mutation-specific prognostication is not yet sufficiently standardized for treatment de-escalation.

Long-term morbidity may include visual loss, cranial neuropathy, anosmia, dysphagia, xerostomia, dental injury, endocrine dysfunction, cognitive effects, and facial/skull-base surgical morbidity. Robust SNUC-specific disability and patient-reported-outcome statistics are unavailable.

12. Treatment and current applications

Standard multidisciplinary strategy

There is no randomized, universally accepted curative algorithm. Care should occur at a high-volume skull-base/head-and-neck center with expert pathology review.

1. Induction chemotherapy: A major contemporary approach uses a platinum doublet to measure chemosensitivity. In a 95-patient treatment-naïve cohort, cisplatin 60–80 mg/m² on day 1 was combined with etoposide 100–120 mg/m² or docetaxel 75 mg/m² on days 1–3 every 21 days for 1–5 cycles (median three). Favorable responders generally had superior outcomes and were often directed to definitive chemoradiation; poor responders with resectable disease were considered for surgery followed by adjuvant therapy. (thawani2023thecontemporarymanagement pages 14-15)
2. Radiotherapy: Definitive or postoperative IMRT, usually at least 60 Gy in the reviewed literature, is a central component. IMRT improves dose conformity near the optic apparatus and brain and was associated in retrospective data with better survival/recurrence outcomes and lower toxicity than older conventional techniques. Proton therapy may reduce normal-tissue dose in selected skull-base cases, but SNUC-specific comparative evidence is limited. (thawani2023thecontemporarymanagement pages 14-15)
3. Surgery: Endoscopic endonasal or craniofacial resection is used when complete resection is anatomically feasible and consistent with functional goals. Open craniofacial resection has increasingly been replaced by endoscopic or combined approaches in selected patients. Surgery alone is inadequate for most advanced SNUCs. (thawani2023thecontemporarymanagement pages 14-15)
4. Systemic agents: Cisplatin, etoposide, docetaxel, paclitaxel, and 5-fluorouracil are used in multimodal regimens. Recurrent/metastatic management is individualized because no SNUC-specific systemic standard has prospective phase III validation.

Suggested NCI Thesaurus intervention concepts include platinum-based chemotherapy, cisplatin, carboplatin, etoposide, docetaxel, paclitaxel, fluorouracil, intensity-modulated radiation therapy, proton-beam radiation therapy, endoscopic resection, craniofacial resection, pembrolizumab, and enasidenib. Exact NCIt codes should be resolved against the current NCIt release rather than inferred.

Recent and emerging research

NeoPeSino—NCT05925491 is a recruiting, single-arm phase II study in 28 planned patients with treatment-naïve stage III–IVB SNUC. It administers pembrolizumab 200 mg, cisplatin 75 mg/m² or carboplatin AUC5, and docetaxel 75 mg/m² every three weeks for three cycles before standard local therapy; the primary endpoint is RECIST 1.1 objective response. The hypothesis is that adding perioperative checkpoint blockade may maintain activity while reducing overall treatment burden, but no efficacy results are yet available. First posted June 29, 2023; ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT05925491. (NCT05925491 chunk 1)

NCT06176989 is an NCI single-arm phase II trial enrolling 40 patients with recurrent/metastatic or unresectable IDH2 R140/R172-mutant sinonasal/skull-base tumors, including SNUC. Enasidenib 100 mg orally daily is given continuously; endpoints include PFS, safety, and SNUC-specific clinical benefit, PFS, and OS. This is the clearest real-world translation of the IDH2 discovery, but it remains experimental. First posted December 20, 2023; ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT06176989. (NCT06176989 chunk 1)

No approved SNUC-specific gene therapy, cell therapy, RNA therapy, CAR-T product, or pharmacogenomic dosing guideline exists. The enasidenib trial also explores UGT1A1 genotype–toxicity association, but this is not yet a validated SNUC pharmacogenomic recommendation. (NCT06176989 chunk 1)

Supportive care should include pain management, nutrition, dental care before radiation, ophthalmology and endocrinology when relevant, swallowing/speech therapy, psychosocial support, smoking cessation, and rehabilitation for visual, neurologic, or functional deficits.

13. Prevention

Primary prevention: No SNUC-specific intervention is proven. Avoid tobacco and minimize occupational exposure to nickel, chromium compounds, metallic and wood dust using engineering controls and personal protective equipment. This is precautionary rather than supported by a quantified SNUC risk reduction. No vaccine is applicable because HPV and EBV are not established causes.

Secondary prevention: Population screening is not recommended because incidence is approximately 0.02/100,000/year and no validated precursor lesion or screening assay exists. Persistent unilateral obstruction, recurrent epistaxis, cranial neuropathy, proptosis, or visual change warrants prompt endoscopic examination and imaging.

Tertiary prevention: Complete multimodal therapy, dental/visual/endocrine protection, rehabilitation, and surveillance imaging aim to reduce recurrence and treatment complications. Genetic counseling and family screening are not routinely indicated because SNUC is not established as inherited.

14. Other species and natural disease

No well-established naturally occurring veterinary counterpart specifically equivalent to molecularly confirmed human SNUC was identified. Dogs, cats, and other animals develop nasal carcinomas, but those should not be annotated as SNUC without matching histology and molecular classification. There is no evidence of zoonotic transmission or cross-species contagion. Comparative orthology of IDH2, TP53, and SWI/SNF genes is strong, but evolutionary conservation alone does not establish a natural-disease model.

15. Model organisms and experimental systems

The retrieved literature did not identify a standardized genetically engineered mouse, rat, zebrafish, organoid, patient-derived xenograft, or authenticated cell-line model that reproducibly recapitulates genuine IDH2-mutant SNUC. Most mechanistic inference comes from human tumor tissue, retrospective cohorts, immunohistochemistry, and targeted sequencing. The 2018 primary study analyzed 53 expert-confirmed SNUCs and 132 mimics, demonstrating diagnostic specificity of mutant-IDH IHC but not providing a causal animal model. (mito2018immunohistochemicaldetectionand pages 1-2)

Priority model-development needs are:

• patient-derived organoids and xenografts retaining IDH2 R172 and native epigenetic state;
• conditional IDH2 R172 knock-in in sinonasal epithelial progenitors;
• isogenic cell systems to test whether mutant IDH2 is sufficient for blocked differentiation;
• immunocompetent models for checkpoint therapy;
• functional screens for IDH, PI3K, DNA-repair, and chromatin dependencies.

Such models would permit testing enasidenib, chemotherapy resistance, radiation response, and rational immunotherapy combinations. Their key limitation will be uncertainty about the human cell of origin and the rarity/heterogeneity of source tissue.

Evidence appraisal and key gaps

The strongest evidence consists of expert-reviewed human pathology cohorts, registry epidemiology, and retrospective multidisciplinary series. There are no randomized SNUC-specific trials, and most treatment comparisons are vulnerable to stage, resectability, institutional, and response-selection bias. Recent molecular classification also means that older cohorts may be contaminated by entities now excluded from SNUC. The most consequential knowledge gaps are validated incidence by modern molecular definition, prospective treatment outcomes, SNUC-specific patient-reported quality of life, immune and single-cell atlases, liquid-biopsy biomarkers, preventive risk estimates, and faithful experimental models.

Principal sources and publication dates

• Thawani R, et al. The contemporary management of cancers of the sinonasal tract in adults. CA Cancer J Clin. 2023;73:72–112. Published online/issue information reported August 2023. DOI/URL: https://doi.org/10.3322/caac.21752. (thawani2023thecontemporarymanagement pages 14-15, thawani2023thecontemporarymanagement pages 12-14)
• Mito JK, et al. Immunohistochemical Detection and Molecular Characterization of IDH-mutant Sinonasal Undifferentiated Carcinomas. Am J Surg Pathol. 2018;42:1067–1075. Published August 2018. DOI/URL: https://doi.org/10.1097/PAS.0000000000001064. Exact abstract conclusion: “IDH-mutant sinonasal carcinoma may represent a distinct pathobiological entity with therapeutic implications.” (mito2018immunohistochemicaldetectionand pages 1-2)
• Agaimy A. SWI/SNF-deficient Sinonasal Neoplasms: An Overview. Head Neck Pathol. 2022;16:168–178. Published March 21, 2022. DOI/URL: https://doi.org/10.1007/s12105-022-01416-x. (agaimy2022proceedingsofthe pages 1-2)
• Turri-Zanoni M, et al. Molecular Biomarkers in Sinonasal Cancers: New Frontiers in Diagnosis and Treatment. Curr Oncol Rep. 2022;24:55–67. Published January 2022. DOI/URL: https://doi.org/10.1007/s11912-021-01154-3. (turrizanoni2022molecularbiomarkersin pages 5-6)

PMIDs were not exposed in the retrieved full-text records and therefore are not fabricated here; DOI links provide stable primary-source resolution.

References

1. (thawani2023thecontemporarymanagement pages 12-14): Rajat Thawani, Myung Sun Kim, Asad Arastu, Zizhen Feng, Malinda T. West, Nicholas F. Taflin, Kyaw Zin Thein, Ryan Li, Mathew Geltzeiler, Nancy Lee, Clifton David Fuller, Jennifer R. Grandis, Charalampos S. Floudas, Michael C. Heinrich, Ehab Hanna, and Ravi A. Chandra. The contemporary management of cancers of the sinonasal tract in adults. CA: A Cancer Journal for Clinicians, 73:72-112, Aug 2023. URL: https://doi.org/10.3322/caac.21752, doi:10.3322/caac.21752. This article has 174 citations and is from a domain leading peer-reviewed journal.

2. (NCT05925491 chunk 1): Pembrolizumab in Locally Advanced Sinonasal Carcinoma. Istituti Clinici Scientifici Maugeri SpA. 2024. ClinicalTrials.gov Identifier: NCT05925491

3. (thawani2023thecontemporarymanagement pages 14-15): Rajat Thawani, Myung Sun Kim, Asad Arastu, Zizhen Feng, Malinda T. West, Nicholas F. Taflin, Kyaw Zin Thein, Ryan Li, Mathew Geltzeiler, Nancy Lee, Clifton David Fuller, Jennifer R. Grandis, Charalampos S. Floudas, Michael C. Heinrich, Ehab Hanna, and Ravi A. Chandra. The contemporary management of cancers of the sinonasal tract in adults. CA: A Cancer Journal for Clinicians, 73:72-112, Aug 2023. URL: https://doi.org/10.3322/caac.21752, doi:10.3322/caac.21752. This article has 174 citations and is from a domain leading peer-reviewed journal.

4. (NCT06176989 chunk 1): Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors. National Cancer Institute (NCI). 2024. ClinicalTrials.gov Identifier: NCT06176989

5. (mito2018immunohistochemicaldetectionand pages 1-2): Jeffrey K. Mito, Justin A. Bishop, Peter M. Sadow, Edward B. Stelow, William C. Faquin, Stacey E. Mills, Jeffrey F. Krane, Christopher A. French, Christopher D.M. Fletcher, Jason L. Hornick, Lynette M. Sholl, and Vickie Y. Jo. Immunohistochemical detection and molecular characterization of idh-mutant sinonasal undifferentiated carcinomas. The American Journal of Surgical Pathology, 42:1067–1075, Aug 2018. URL: https://doi.org/10.1097/pas.0000000000001064, doi:10.1097/pas.0000000000001064. This article has 70 citations.

6. (agaimy2022proceedingsofthe pages 1-2): Abbas Agaimy. Proceedings of the north american society of head and neck pathology, los angeles, ca, march 20, 2022: swi/snf-deficient sinonasal neoplasms: an overview. Head and Neck Pathology, 16:168-178, Mar 2022. URL: https://doi.org/10.1007/s12105-022-01416-x, doi:10.1007/s12105-022-01416-x. This article has 31 citations and is from a peer-reviewed journal.

7. (konig2020theroleof pages 5-6): Marton König, Terje Osnes, Øyvind Bruland, Kirsten Sundby Hall, Åse Bratland, and Torstein R. Meling. The role of adjuvant treatment in craniofacial malignancy: a critical review. Frontiers in Oncology, Aug 2022. URL: https://doi.org/10.3389/fonc.2020.01402, doi:10.3389/fonc.2020.01402. This article has 10 citations.

8. (turrizanoni2022molecularbiomarkersin pages 5-6): Mario Turri-Zanoni, Giacomo Gravante, and Paolo Castelnuovo. Molecular biomarkers in sinonasal cancers: new frontiers in diagnosis and treatment. Current Oncology Reports, 24:55-67, Jan 2022. URL: https://doi.org/10.1007/s11912-021-01154-3, doi:10.1007/s11912-021-01154-3. This article has 40 citations and is from a peer-reviewed journal.

9. (thawani2023thecontemporarymanagement pages 62-70): Rajat Thawani, Myung Sun Kim, Asad Arastu, Zizhen Feng, Malinda T. West, Nicholas F. Taflin, Kyaw Zin Thein, Ryan Li, Mathew Geltzeiler, Nancy Lee, Clifton David Fuller, Jennifer R. Grandis, Charalampos S. Floudas, Michael C. Heinrich, Ehab Hanna, and Ravi A. Chandra. The contemporary management of cancers of the sinonasal tract in adults. CA: A Cancer Journal for Clinicians, 73:72-112, Aug 2023. URL: https://doi.org/10.3322/caac.21752, doi:10.3322/caac.21752. This article has 174 citations and is from a domain leading peer-reviewed journal.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.